NasdaqCM:GOVX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	24	-26	N/A	N/A	1
12/31/2024	N/A	-31	N/A	N/A	2
3/31/2024	N/A	-28	-27	-27	N/A
12/31/2023	N/A	-26	-25	-25	N/A
9/30/2023	N/A	-24	-22	-22	N/A
6/30/2023	N/A	-19	-21	-21	N/A
3/31/2023	N/A	-16	-19	-18	N/A
12/31/2022	0	-14	-19	-19	N/A
9/30/2022	0	-22	-19	-19	N/A
6/30/2022	0	-20	-17	-16	N/A
3/31/2022	0	-19	-14	-14	N/A
12/31/2021	0	-19	-11	-11	N/A
9/30/2021	0	-6	-6	-6	N/A
6/30/2021	1	-5	-5	-5	N/A
3/31/2021	1	-4	-4	-4	N/A
12/31/2020	2	-3	-3	-3	N/A
9/30/2020	2	-2	-1	-1	N/A
6/30/2020	2	-2	-2	-2	N/A
3/31/2020	2	-2	-1	-1	N/A
12/31/2019	1	-2	-1	-1	N/A
9/30/2019	1	-2	-2	-2	N/A
6/30/2019	1	-3	-2	-2	N/A
3/31/2019	1	-3	-1	-1	N/A
12/31/2018	1	-3	-2	-2	N/A
9/30/2018	1	-2	-1	-1	N/A
6/30/2018	1	-2	-2	-2	N/A
3/31/2018	1	-2	-2	-2	N/A
12/31/2017	1	-2	N/A	-2	N/A
9/30/2017	1	-3	N/A	-2	N/A
6/30/2017	1	-2	N/A	-2	N/A
3/31/2017	1	-3	N/A	-2	N/A
12/31/2016	1	-3	N/A	-2	N/A
9/30/2016	1	-3	N/A	-2	N/A
6/30/2016	0	-3	N/A	-3	N/A
3/31/2016	0	-3	N/A	-3	N/A
12/31/2015	0	-3	N/A	-3	N/A
9/30/2015	0	-3	N/A	-3	N/A
6/30/2015	1	-3	N/A	-2	N/A
3/31/2015	1	-3	N/A	-2	N/A
12/31/2014	1	-3	N/A	-2	N/A
9/30/2014	1	-3	N/A	-2	N/A
6/30/2014	2	-2	N/A	-2	N/A
3/31/2014	2	-2	N/A	-2	N/A
12/31/2013	2	-2	N/A	-2	N/A
9/30/2013	3	-2	N/A	-1	N/A
6/30/2013	2	-2	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GOVX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GOVX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: GOVX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GOVXの収益 ( 158.7% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: GOVXの収益 ( 158.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GOVXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

GeoVax Labs 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 14% to US$120

Price target increased by 14% to US$120

Price target decreased to US$5.50

Recent updates

GeoVax Labs Receives a Notice from Nasdaq Regarding Non-Compliance with Minimum $2.5 Million Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q1, 2024 Results on May 14, 2024

GeoVax Labs, Inc., Annual General Meeting, May 23, 2024

GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System

New minor risk - Shareholder dilution

Price target increased by 14% to US$120

GeoVax Labs, Inc. to Report Q4, 2023 Results on Feb 29, 2024

GeoVax Labs Regains Compliance with Nasdaq Minimum Bid Requirement

Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster

GeoVax Announces 1 for 15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Geovax Appoints Marc Pipas as Executive Medical Director, Oncology

New major risk - Market cap size

GeoVax Labs Receives a Notice from the Nasdaq Stock Market

Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02

New major risk - Revenue and earnings growth

GeoVax Labs, Inc. to Report Q3, 2023 Results on Nov 08, 2023

GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

New major risk - Financial position

GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc. to Report Q2, 2023 Results on Aug 09, 2023

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GeoVax Labs, Inc., Annual General Meeting, Aug 01, 2023

GeoVax Labs, Inc. Announces Next-Generation COVID-19 Vaccine Data to Be Presented At Two Upcoming Scientific Meetings

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Geovax Labs, Inc. Appoints Valerie Montgomery Rice as Special Advisor to the Chairman/CEO and Board of Directors

GeoVax Labs Receives Non-Compliance Notice From Nasdaq

GeoVax Labs, Inc. Appoints Jayne Morgan to Board of Directors

Price target decreased to US$5.50

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.31 loss in 3Q 2021)

High number of new directors

GeoVax Labs, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

Geovax Announces Appointment of Nicole Lemerond to Its Board of Directors

GeoVax: Possible Vaccine Advancements In 2 Big Indications

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

GeoVax Labs, Inc. to Report Q2, 2022 Results on Aug 03, 2022

GeoVax Labs, Inc., Annual General Meeting, Aug 03, 2022

Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky

First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.29 loss in 1Q 2021)

Insufficient new directors

GeoVax Labs, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Geovax Labs, Inc. Announces Management Appointments

GeoVax Labs, Inc. to Report Fiscal Year 2021 Results on Mar 09, 2022

GeoVax Labs, Inc. announced that it has received $9.999998 million in funding

GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation

GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial for Covid-19 Vaccine Booster

GeoVax Labs, Inc. Presents Hemorrhagic Fever Vaccine Data at World Vaccine & Immunotherapy Congress

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.31 loss per share (vs US$0.73 loss in 3Q 2020)

GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program

Geovax Presents Covid-19 Vaccine Data At the European Society of Medicine (Esmed) General Assembly

We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.66 loss in 2Q 2020)

GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting

First quarter 2021 earnings released: US$0.29 loss per share (vs US$2.54 loss in 1Q 2020)

Full year 2020 earnings released: US$2.14 loss per share

GeoVax Labs, Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

GeoVax Expands and Strengthens Intellectual Property Portfolio

Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?

New 90-day high: US$7.71

New 90-day high: US$5.95

GeoVax soars on NIAID grant for COVID-19 vaccine candidate

GeoVax Announces License Agreement With NIH to Support Continued Advancements in Vaccine Development

New 90-day low: US$2.73

GeoVax Labs, Inc. to Report Q3, 2020 Results on Nov 05, 2020